Editing Genentech (section)

==Products timeline==
* 1982: Synthetic "human" [[insulin]] approved by the [[U.S. Food and Drug Administration]] (FDA), partnered with insulin manufacturer [[Eli Lilly and Company]], who shepherded the product through the FDA approval process.  The product ([[Humulin]]) was licensed to and manufactured by Lilly, and was the first-ever approved genetically engineered human therapeutic.
* 1985: [[Protropin]] (somatrem): Supplementary [[growth hormone]] for children with [[growth hormone deficiency]] (ceased manufacturing 2004).
* 1987: [[Activase]] (alteplase): A recombinant [[tissue plasminogen activator]] (tPa) used to dissolve blood clots in patients with acute [[myocardial infarction]]. Also used to treat non-hemorrhagic stroke.
* 1990: [[Actimmune]] ([[Interferon|interferon gamma 1b]]): Treatment of [[chronic granulomatous disease]] (licensed to Intermune).
* 1993: [[Nutropin]] (recombinant somatropin): [[Growth hormone]] for children and adults for treatment before [[kidney transplant]] due to [[chronic kidney disease]].
* 1993: [[Pulmozyme]] (dornase alfa): Inhalation treatment for children and young adults with [[cystic fibrosis]]—recombinant [[DNAse]].
* 1997: [[Rituximab|Rituxan]] (rituximab): Treatment for specific kinds of [[non-Hodgkin's lymphomas]]. In 2006, also approved for [[rheumatoid arthritis]].
* 1998: [[Trastuzumab|Herceptin]] (trastuzumab): Treatment for [[metastatic breast cancer]] patients with tumors that overexpress the [[HER2]] gene. Recently approved for adjuvant therapy for breast cancer. FDA also recently approved Trastuzumab for metastatic gastric cancer with HER2 receptor site positive.
* 2000: [[TNKase]] (tenecteplase): "[[Thrombolysis|Clot-busting]]" drug to treat acute [[myocardial infarction]].
* 2003: [[Omalizumab|Xolair]] (omalizumab): Subcutaneous injection for moderate to severe persistent [[asthma]].
* 2003: [[Efalizumab|Raptiva]] (efalizumab): Antibody designed to block the activation and reactivation of [[T cell]]s that lead to the development of [[psoriasis]]. Developed in partnership with [http://www.xoma.com XOMA]. In 2009, voluntary U.S. market withdrawal after reports of [[progressive multifocal leukoencephalopathy]].
* 2004: [[Bevacizumab|Avastin]] (bevacizumab): Anti-VEGF [[monoclonal antibody]] for the treatment of metastatic cancer of the [[colon (anatomy)|colon]] or [[rectum]].  In 2006, also approved for locally advanced, recurrent or metastatic [[non-small cell lung cancer]].  In 2008, accelerated approval was granted for Avastin in combination with chemotherapy for previously untreated advanced HER2-negative breast cancer.  In 2009, Avastin gained its fifth approval for treatment of [[glioblastoma multiforme]], and sixth approval for the treatment of metastatic [[renal cell carcinoma]]. It was most publicized for its approval in advanced breast cancer treatment, but the FDA approval for breast cancer treatment was subsequently revoked in November 2011.
* 2004: [[Erlotinib|Tarceva]] (erlotinib): Treatment for patients with locally advanced or metastatic non-small cell lung cancer, and pancreatic cancer.
* 2006: [[Ranibizumab|Lucentis]] (ranibizumab injection): Treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA approved LUCENTIS after a Priority Review (six-month). Genentech started shipping product on June 30, 2006, the day the product was approved.
* 2010: [[Actemra]] (tocilizumab): The first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat rheumatoid arthritis.
* 2011: [[Vemurafenib|Zelboraf]] (vemurafenib): For the treatment of [[metastatic melanoma]] caused by [[BRAF (gene)|BRAF]] mutation.
* 2012: [[Erivedge]] (vismodegib): Treatment for advanced [[basal-cell carcinoma]] (BCC).  A small molecule inhibitor that targets a key protein in the [[Hedgehog signaling pathway]].  This is the first approved therapy for advanced BCC.
* 2012: [[Pertuzumab|Perjeta]] (pertuzumab): For use in combination with Herceptin (trastuzumab) and [[docetaxel]] chemotherapy for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
* 2013: [[trastuzumab emtansine|Kadcyla]] (ado-trastuzumab emtansine): The first Genentech antibody-drug conjugate (ADC) to receive FDA approval. It consists of trastuzumab (Herceptin) linked to a cytotoxic agent mertansine (DM1), used in the treatment of HER2-positive metastatic breast cancer.
* 2013: [[Obinutuzumab|Gazyva]] (obinutuzumab): For use in combination with chlorambucil to treat patients with previously untreated [[chronic lymphocytic leukemia]] (CLL). Gazyva is the first drug with [[breakthrough therapy]] designation to receive FDA approval.
* 2014: [[Pirfenidone|Esbriet]] (pirfenidone): An anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF). Developed by Intermune, Inc.
* 2015: [[Cobimetinib|Cotellic]] (cobimetinib): For use in combination with ZELBORAF (vemurafenib), to treat [[metastatic melanoma]] caused by [[BRAF (gene)|BRAF]] mutation.
* 2015: [[Alectinib|Alecensa]] (alectinib): Treatment for non-small cell lung cancer (NSCLC).
* 2016: [[Venetoclax|Venclexta]] (venetoclax): Treatment for patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy.
* 2016: [[Tecentriq]] (atezolizumab): First-in-class anti-PD-L1 antibody for the treatment of advanced bladder cancer or metastatic non-small cell lung cancer (NSCLC), both after failure of platinum-based chemotherapy. Tecentriq was granted accelerated approval for its advanced bladder cancer indication due to promising phase II results.
* 2017: [[Ocrelizumab|Ocrevus]] (ocrelizumab): The first FDA-approved therapy that treats both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The PPMS form of the disease previously had no approved treatments.
* 2017: [[Emicizumab|Hemlibra]] (emicizumab): Treatment for haemophilia A. Developed by [[Chugai Pharmaceutical Co.]]
* 2018: [[Baloxavir marboxil|Xofluza]] (Baloxavir marboxil): Antiviral medication for treatment of influenza A and influenza B. Developed by [[Shionogi]].
* 2019: [[Polatuzumab vedotin|Polivy]] (Polatuzumab vedotin-piiq): Treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.